Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

Cancers, Journal Year: 2024, Volume and Issue: 16(5), P. 1029 - 1029

Published: March 2, 2024

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy often a preferred therapeutic option. Biomarker-based stratification mCRC enables use precision therapy based on individual tumor mutational profiles. Activating mutations in RAS/RAF/MAPK pathway downstream EGFR signaling have, until recently, limited EGFR-targeted therapies mCRC; however, development anti-RAS and anti-RAF together with improved strategies to limit compensatory pathways resulting survival rates several highly lethal sub-types (e.g., BRAF-mutant). The fluoropyrimidine (FP)-based regimens treat continues evolve contributing long-term survival. Future advances will need position relative made oncology.

Language: Английский

---

Use of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Combined With Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19‐9 in Predicting Colorectal Cancer Liver Metastasis

Journal of Clinical Ultrasound, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with serum carcinoembryonic antigen (CEA) and carbohydrate 19-9 (CA19-9) levels to evaluate the efficacy of colorectal cancer liver metastasis (CRCLM) treatment is still rare.

Language: Английский

---

Colorectal Cancer: Current Updates and Future Perspectives

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 13(1), P. 40 - 40

Published: Dec. 21, 2023

Colorectal cancer is a frequent neoplasm in western countries, mainly due to dietary and behavioral factors. Its incidence growing developing countries for the westernization of foods lifestyles. An increased rate observed patients under 45 years age. In recent years, mortality CRC decreased, but this trend slowing. The reducing those where prevention treatments have been implemented. survival over 65%. This reflects earlier detection through routine clinical examinations screening, more accurate staging advances imaging, improvements surgical techniques, chemotherapy radiation. most important predictor stage at diagnosis. screening programs are able reduce rates CRC. aim paper provide comprehensive overview incidence, mortality,

Language: Английский

---

Comparative evaluation of non-contrast MRI versus gadoxetic acid-enhanced abbreviated protocols in detecting colorectal liver metastases

Insights into Imaging, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 2, 2025

Abstract Purpose This study compares the diagnostic efficacy of non-contrast abbreviated MRI protocols with Gadoxetic acid-enhanced for detecting colorectal liver metastasis (CRLM), focusing on lesion characterization and surveillance. Methods Ninety-four patients, including 55 pathologically verified CRLM, were enrolled, totaling 422 lesions (287 metastatic, 135 benign). Two independent readers assessed three per patient: Protocol 1 included sequences (T2-weighted turbo spin-echo, T1-weighted Dixon, diffusion-weighted imaging (DWI), ADC mapping). 2 gadoxetic acid enhancement hepatobiliary phase imaging, T2 TSE, DWI, maps. 3 utilized standard Acid-enhanced sequence, which pre-contrast Dixon sequences, post-contrast (including arterial, portal venous, transitional phases), additional T2-weighted DWI sequences. Diagnoses scored a 5-point scale (benign = 1; malignant 5), scores ≥ indicating CRLM. ROC curves analyzed accuracy, comparing area under curve (AUC) values across protocols. Results No significant difference in AUCs was observed between (0.899–0.909) (0.906–0.931) versus (0.935–0.939) ( p 0.091–0.195). For ≤ 10 mm, slightly inferior to 0.002–0.032), while remained comparably effective 0.096–0.179). These findings held when using threshold 4 define Conclusion The non-enhanced protocol is as identifying proposed Ab-MRI approach may be viable alternative CRLM Critical relevance statement (Ab-MRI) (CRLM). Key Points are (CRLM) showed equivalent more cost-effective. Graphical

Language: Английский

---

Impact of Intraoperative Blood Loss on Postoperative Morbidity after Liver Resection for Primary and Secondary Liver Cancer

HPB, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Evaluation of circulating glypican 4 as a novel biomarker in disease – A comprehensive review

Journal of Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Language: Английский

---

Multicenter Belgian prospective registry on minimally invasive and open liver surgery (BReLLS): experience from 1342 consecutive cases

Langenbeck s Archives of Surgery, Journal Year: 2025, Volume and Issue: 410(1)

Published: March 3, 2025

Abstract Purpose Minimally invasive liver surgery (MILS) still appears to be adopted with significant variability. We aimed investigate the diffusion, indications, and short-term outcomes of MILS compared open approach. Methods A prospective registry all resections performed for any indication using technique between January 1, 2017, December 31, 2019, was established (BReLLS) analyzed. Results total 1342 consecutive were included, 684 (51%) 658 (49%) procedures. not attempted due technical complexity in 46.2% cases, followed by previous abdominal (22.5%). Patients undergoing had a higher proportion benign indications hepatocellular carcinomas, patients affected cirrhosis portal hypertension lower major hepatectomies (all p < 0.001). After propensity-score matching, showed better results terms duration ( 0.001), blood loss = 0.015), complication rate Clavien-Dindo grade ≥ 3 complications 0.012), comprehensive index length stay readmissions 0.016). Centers performing over 50 per year overall cases similar 0.362), but prevalence 0.004), 90-day mortality rates shorter hospital Conclusion preferred half particularly hypertension, lesions. It provided superior approach both minor selected patients.

Language: Английский

---

Enhancing Rectal Cancer Staging: Integrating Abbreviated Liver MRI into Standard Rectal MRI Protocols for Improved Diagnostic Utility

Journal of the Korean Society of Radiology, Journal Year: 2025, Volume and Issue: 86

Published: Jan. 1, 2025

Language: Английский

---

Enhancing Outcome Prediction in Patients with Colorectal Liver Metastasis Undergoing Hepatectomy: The Synergistic Impact of FIB-4 Index and Tumor Burden Score Across KRAS Profiles

HPB, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

Clinical outcomes of parenchymal-sparing versus anatomic resection for colorectal liver metastases: a systematic review and meta-analysis

World Journal of Surgical Oncology, Journal Year: 2023, Volume and Issue: 21(1)

Published: Aug. 8, 2023

Abstract Background The advantages of parenchymal-sparing resection (PSR) over anatomic (AR) colorectal liver metastases (CRLM) remain controversial. Here, we aim to evaluate their safety and efficacy. Methods A systematic review meta-analysis short-term perioperative outcomes long-term oncological for PSR AR were performed by searching Pubmed, Embase, the Cochrane Library Web Science databases. Results Twenty-two studies considered eligible (totally 7228 patients: AR, n = 3154 (43.6%) vs. PSR, 4074 (56.4%)). Overall survival (OS, HR 1.08, 95% CI: 0.95-1.22, P 0.245) disease-free (DFS, 1.09, 0.94-1.28, 0.259) comparable between two groups. There no significant differences in 3-year OS, 5-year DFS, recurrence-free (liver-RFS) liver-RFS. In terms outcome, patients undergoing surgery associated with prolonged operation time (WMD 51.48 min, 29.03-73.93, < 0.001), higher amount blood loss 189.92 ml, 21.39-358.45, 0.027), increased intraoperative transfusion rate (RR 2.24, 1.54-3.26, hospital stay 1.00 day, 0.34-1.67, 0.003), postoperative complications 2.28, 1.88-2.77, 90-day mortality 3.08, 1.88-5.03, 0.001). While was positive margins 0.77, 0.61-0.97, 0.024), intrahepatic recurrence 0.90, 0.82-0.98, 0.021) repeat hepatectomy 0.64, 0.55-0.76, Conclusion Considering relatively acceptable heterogeneity, had better without compromising outcomes. However, these findings must be carefully interpreted, requiring more supporting evidence. Trial registration PROSPERO number: CRD42023445332.

Language: Английский

---